Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease

Journal of Alzheimer's Disease : JAD
Cyntia TremblayFrédéric Calon

Abstract

We report a post mortem biochemical analysis of amyloid-beta (Abeta) (ELISA) and tau (Western immunoblots) in the temporo-parietal neocortex of subjects with a clinical diagnosis of mild cognitive impairment (MCI, n=12), Alzheimer's disease (AD, n=12) or no cognitive impairment (NCI, n=12). Levels of Abeta _{42} in the detergent-insoluble protein fractions were significantly higher in persons with AD but did not differentiate individuals with MCI. Conversion of tau into its insoluble form (soluble/insoluble tau ratio) or into paired helical filament tau (PHF_{tau}) were the biochemical variables most closely related to clinical and neuropathological diagnoses, but they did not distinguished MCI from the two other groups. Interestingly, soluble/insoluble total tau ratio, PHF_{tau} and insoluble Abeta_{42} concentrations in the cortex correlated strongly with global cognition scores proximate to death and with immunohistochemical and histological quantification of Abeta and tau pathologies. Our data suggest that 1) insoluble Abeta _{42} and insoluble tau (total or PHF_{tau}) show a significant relationship with the clinical and neuropathological diagnosis of AD; 2) Although MCI appears to represent an intermediate stage between N...Continue Reading

Citations

Aug 24, 2010·The European Journal of Neuroscience·Laura K HamiltonKarl J L Fernandes
Jul 3, 2015·Frontiers in Aging Neuroscience·Milene VandalFrédéric Calon
Jun 26, 2015·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Milene VandalFrederic Calon
Dec 23, 2015·Acta Neuropathologica·Isabelle St-AmourFrédéric Calon
Sep 24, 2016·Journal of Alzheimer's Disease : JAD·Alexandre Dal-PanUNKNOWN Neurophenols consortium
Mar 15, 2008·Journal of Neuroscience Research·Carl JulienFrédéric Calon
Dec 19, 2014·The International Journal of Neuropsychopharmacology·Janelle Drouin-OuelletFrancesca Cicchetti
Nov 2, 2019·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Andréa L BenedetPedro R Neto
Dec 24, 2008·Journal of Neuropathology and Experimental Neurology·Carl JulienFrédéric Calon
Feb 9, 2010·The FEBS Journal·Ola PhilipsonLars N G Nilsson
Feb 18, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Charlotte DelayFrédéric Calon
Sep 13, 2015·Human Molecular Genetics·Pascal Y SmithSébastien S Hébert
Dec 19, 2018·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Marine TournissacFrederic Calon
Aug 26, 2011·Journal of Neuropathology and Experimental Neurology·Cyntia TremblayFrédéric Calon
Nov 22, 2011·Acta Neuropathologica·Elliott J MufsonStephen W Scheff
Nov 29, 2011·Brain : a Journal of Neurology·Sarah Paris-RobidasFrédéric Calon
Dec 16, 2020·Acta Neuropathologica·Diego Sepulveda-FallaMarkus Glatzel
Sep 3, 2021·Heliyon·Enrique Montiel-FloresMaria Rosa Avila-Costa
Oct 18, 2008·Neurobiology of Aging·Carl JulienFrédéric Calon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.